CD8A and non-small cell lung carcinoma: More recently, a study showed that the ratio of CD8+ T cells to neutrophils within the tumor could separate patients responsive to anti-PD-1 therapy from those with stable or progressive disease in non-small cell lung cancer (NSCLC) [30].